Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Treasury Shares (2021 - 2025)

CytomX Therapeutics (CTMX) has disclosed Treasury Shares for 5 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Treasury Shares rose 85.02% year-over-year to $2.9 million, compared with a TTM value of $2.9 million through Sep 2025, up 85.02%, and an annual FY2024 reading of $1.2 million, up 36.0% over the prior year.
  • Treasury Shares was $2.9 million for Q3 2025 at CytomX Therapeutics, up from $585000.0 in the prior quarter.
  • Across five years, Treasury Shares topped out at $2.9 million in Q3 2025 and bottomed at $585000.0 in Q2 2025.
  • Average Treasury Shares over 5 years is $1.3 million, with a median of $1.1 million recorded in 2023.
  • Peak annual rise in Treasury Shares hit 85.02% in 2025, while the deepest fall reached 65.28% in 2025.
  • Year by year, Treasury Shares stood at $868250.0 in 2021, then soared by 39.69% to $1.2 million in 2022, then decreased by 27.86% to $875000.0 in 2023, then soared by 36.0% to $1.2 million in 2024, then skyrocketed by 144.1% to $2.9 million in 2025.
  • Business Quant data shows Treasury Shares for CTMX at $2.9 million in Q3 2025, $585000.0 in Q2 2025, and $860000.0 in Q1 2025.